28 February 2018
PharmaPoint

24 Market Reports adds “Global PharmaPointRheumatoid Arthritis Drug Market Professional Survey Report 2018” new report to its research database. The globalPharmaPointRheumatoid Arthritis Drug market report has been segmented on the basis of product, allergen, tests, end user, and region.

Summary

Rheumatoid arthritis RA is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over six million individuals in the 8MM covered in this report US, France, Germany, Italy, Spain, UK, Japan, and Australia and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The antiTNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2015 and 2025. With the antiTNFs as extremely effective for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars launch across the 8MM and begin to gain traction in these markets.

Scope

Overview of rheumatoid arthritis RA, including etiology, pathophysiology, and countryspecific diagnosis and treatment recommendations.
Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors such as Eli Lilly/Incyte’s Olumiant baricitinib, novel biologics such as AstraZenecaMedImmune’s mavrilimumab, and biosimilars such as Celltrion/Hospira/Pfizer’s Inflectra/Remsima, Samsung Bioepis/Biogen/Merck’s Flixabi and Benepali, Sandoz’s Erelzi, and Amgen’s Amjevita.
Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/pharmapoint-rheumatoid-arthritis---global-drug-forecast-and-market-analysis-to-2025

Reasons to buy

The report will enable you to
Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the RA market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Track drug sales in the eight major RA markets from 20152025.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

You can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.

Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/pharmapoint-rheumatoid-arthritis---global-drug-forecast-and-market-analysis-to-2025

Table of content

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 25
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 27
3.2 Symptoms 32
3.3 Prognosis 32
3.4 Quality of Life 33
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and Comorbidities 35
4.3 Global Trends 36
4.3.1 Diagnosed Incidence 37
4.3.2 Prevalence 39
4.4 Forecast Methodology 41
4.4.1 Sources Used 41
4.4.2 Forecast Assumptions and Methods 45
4.4.3 Sources Not Used 55
4.5 Epidemiological Forecast for RA 20152025 55
4.5.1 Diagnosed Incident Cases 55
4.5.2 Diagnosed Prevalent Cases 62
4.5.3 Total Prevalent Cases 70
4.6 Discussion 77
4.6.1 Epidemiological Forecast Insight 77
4.6.2 Limitations of the Analysis 78
4.6.3 Strengths of the Analysis 79
5 Disease Management 80
5.1 Diagnosis and Treatment Overview 80
5.1.1 Diagnosis 80
5.1.2 Treatment Guidelines 82
5.1.3 Leading Prescribed $@!#% for the Treatment of RA 92
5.1.4 Clinical Practice 93
5.2 US 94
5.3 France 97
5.4 Germany 99
5.5 Italy 102
5.6 Spain 104
5.7 UK 106
5.8 Japan 108
5.9 Australia 110
6 Competitive Assessment 112
6.1 Overview 112
6.2 Product Profiles Major Brands 113
6.2.1 Enbrel etanercept 113
6.2.2 Humira adalimumab 119
6.2.3 Remicade infliximab 123
6.2.4 Simponi golimumab 129
6.2.5 Cimzia certolizumab pegol 134
6.2.6 Orencia abatacept 139
6.2.7 Actemra/RoActemra tocilizumab 145

If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/pharmapoint-rheumatoid-arthritis---global-drug-forecast-and-market-analysis-to-2025

CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: help@24marketreports.com

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports

  • 2k
    Vews
  • 8
    Avg Daily Vews
  • 1 Day
  • 1 Week
  • 1 Month
  • 2 Months
  • 6 Months
  • 1 Year
0 Comments